Pancreatic Ductal Adenocarcinoma (PDAC) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Pancreatic Ductal Adenocarcinoma (PDAC) Emerging Therapy and TPP Insights

Thelansis’s “Pancreatic Ductal Adenocarcinoma (PDAC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Pancreatic Ductal Adenocarcinoma (PDAC) Overview

Pancreatic Ductal Adenocarcinoma (PDAC) is the most prevalent and lethal form of pancreatic cancer, characterized by originating in the exocrine duct cells and having an exceptionally poor prognosis due to its typically asymptomatic early stages and late diagnosis in locally advanced or metastatic phases. Biologically, PDAC is driven by near-universal mutations in the KRAS oncogene, coupled with frequent inactivation of tumor suppressors like CDKN2A, TP53, and SMAD4. A hallmark challenge is the extensive, dense, and immune-suppressive desmoplastic tumor microenvironment (TME) that creates a physical barrier limiting drug delivery. Diagnosis relies on imaging and biopsy to confirm the cancer and determine staging, which dictates treatment strategy. While surgical resection (e.g., the Whipple procedure) offers the only chance for cure in the minority of eligible patients, the backbone of systemic treatment involves potent chemotherapy regimens like FOLFIRINOX, with targeted therapies limited to rare subsets, such as PARP inhibitors for patients with BRCA mutations.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)